3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
2
Terminated
1
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
7
CNS
5
Endocrine
4
Dermatologic
4
Tumor-Agnostic
2
Thoracic
2
Gastrointestinal
2
Plasma cell
1
Other solid neoplasm
1
Other neoplasm
1
Other hematologic neoplasm
1
Other
1
Myeloid
1
Lymphoid
1
Conditions
Neoplasms
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Interventions
Cyclophosphamide
170
Rituximab
143
Specimen Handling
82
venetoclax
79
fludarabine
78
Vincristine
69
obinutuzumab
67
Doxorubicin
66
Prednisone
65
Biopsy
64
Magnetic Resonance Spectroscopy
62
zanubrutinib
52
Lenalidomide
52
Dexamethasone
49
Methotrexate
43
Cytarabine
43
blinatumomab
40
acalabrutinib
37
Immunotherapy, Adoptive
37
Bendamustine Hydrochloride
37
Etoposide
32
fludarabine phosphate
31
ibrutinib
28
glofitamab
28
polatuzumab vedotin
26
pirtobrutinib
24
orelabrutinib
24
Gemcitabine
23
Injections
21
Mercaptopurine
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
dabrafenib
×
Lymphoid
×
Clear all
NCT02693535
2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled